BriaCell Therapeutics Corp.
BCTX
$10.08
$0.080.80%
NASDAQ
| 07/31/2025 | 04/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.55% | 2.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.18% | -11.73% | |||
| Operating Income | -35.18% | 11.73% | |||
| Income Before Tax | -31.15% | 1.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.15% | 1.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -25.82% | 111.21% | |||
| Net Income | -32.06% | 2.61% | |||
| EBIT | -35.18% | 11.73% | |||
| EBITDA | -35.32% | 11.78% | |||
| EPS Basic | 43.75% | 29.62% | |||
| Normalized Basic EPS | 43.12% | 29.99% | |||
| EPS Diluted | 43.68% | 29.62% | |||
| Normalized Diluted EPS | 43.12% | 29.99% | |||
| Average Basic Shares Outstanding | 134.77% | 38.37% | |||
| Average Diluted Shares Outstanding | 134.77% | 38.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||